Navigation Links
DURECT Announces Changes to its Board of Directors
Date:9/27/2013

CUPERTINO, Calif., Sept. 27, 2013 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Jay Shepard will join its Board of Directors effective September 26, 2013.  Separately, Michael Casey has made the decision to retire from the Board of Directors effective December 31, 2013. 

(Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO)

Mr. Shepard has over 30 years' experience in the pharmaceutical, biotechnology and drug delivery fields.  Mr. Shepard currently serves as an Executive Partner at Sofinnova Ventures.  From 2010 until 2012, he was President and CEO of NextWave Pharmaceuticals, a pediatric focused therapeutics company which was acquired in November 2012 by Pfizer in a deal valued up to $700 million shortly after NextWave obtained FDA approval for Quillivant XR, a treatment for Attention-Deficit Hyperactivity Disorder (ADHD).  While serving at NextWave, Mr. Shepard maintained a strategic adviser relationship with Sofinnova Ventures, which he joined in 2008 as an Executive in Residence.  Prior to Sofinnova Ventures, Mr. Shepard was President and CEO of Ilypsa, a nephrology therapeutics company acquired by Amgen for $420 million.  He then helped with Ilypsa's spin-out company, Relypsa, serving as interim President and CEO.  Before Ilypsa, Mr. Shepard served as Vice President, Commercial Operations at Telik, where he was responsible for all activities related to market preparation toward the launch of the company's lead oncology compounds.  Previously, he was Vice President of ALZA Pharmaceuticals' Oncology Business Unit, having held leadership positions of increasing responsibility in the establishment and operation of ALZA's specialty pharmaceutical sales and marketing group.  Mr. Shepard began his career in pharmaceutical sales and marketing at Ortho Pharmaceutical and Syntex Laboratories.     

"We look forward to the commercial perspective Jay Shepard will bring to our Board of Directors as we evaluate and execute on the partnering, development opportunities and market introduction for our product pipeline," said Dr. Felix Theeuwes, DURECT's Chairman and Chief Scientific Officer. "Mike Casey has decided to retire from our Board at the end of the year in order to spend additional time pursuing personal interests.  We have benefited greatly from Mike Casey's commercial insight during his 9 years of dedicated service as a member of the Board of Directors, and we thank him for his valuable counsel and strategic input to the Company."

"This is a very exciting time for DURECT, given the February 2014 PDUFA date for POSIDUR and the other programs in development, and I look forward to assisting management and the Board of Directors as they face a number of strategic decisions around that pipeline," stated Jay Shepard.     

About DURECT Corporation
DURECT is a specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including Remoxy®, POSIDUR, ELADUR®, and TRANSDUR®-Sufentanil.  DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs.  For more information, please visit www.durect.com.

DURECT Forward-Looking Statement
The statements in this press release regarding POSIDUR and its PDUFA date in February 2014, and the potential market introduction of other products in the company's pipeline are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, the risk of adverse decisions by regulatory agencies, including product non-approval, delays and additional costs due to requirements imposed by regulatory agencies, the risk that the FDA will not complete review of the POSIDUR NDA by the PDUFA date, potential adverse effects arising from additional testing or use of POSIDUR, the potential that the data that we have generated may not be deemed sufficient by FDA or other regulatory agencies to support regulatory approval of POSIDUR, our potential inability to license rights to POSIDUR on commercially acceptable terms, or at all, and the risk of obtaining marketplace acceptance of POSIDUR, avoiding infringing patents held by other parties and securing and defending patents of our own, and managing and obtaining capital to fund our growth, operations and expenses. Further information regarding these and other risks is included in DURECT's Form 10-Q on August 6, 2013 under the heading "Risk Factors."

NOTE: POSIDUR, SABER®, TRANSDUR®, and ELADUR are trademarks of DURECT Corporation. Remoxy, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.


'/>"/>
SOURCE DURECT Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. DURECT Corporation Announces Second Quarter 2013 Financial Results and Update of Programs
2. DURECT Corporation Announces First Quarter 2013 Financial Results and Update of Programs
3. DURECT Corporation Invites You to Join its First Quarter 2013 Earnings Conference Call
4. DURECT Corporation Invites You to Join its Fourth Quarter 2012 Earnings Conference Call
5. DURECT Corporation Announces Third Quarter 2012 Financial Results and Update of Programs
6. DURECT Corporation Invites You to Join its Third Quarter 2012 Earnings Conference Call
7. DURECT to Participate in Upcoming Healthcare Conferences
8. DURECT Corporation Announces Second Quarter 2012 Financial Results and Update of Programs
9. DURECT Corporation Announces First Quarter 2012 Financial Results and Update of Programs
10. DURECT Announces Issuance of U.S. Patents Covering ORADUR® Technology
11. Trianni Announces Launch of Its Optimized Human Antibody Transgenic Mouse
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... June 26, 2016 Story ... operating models within the health care industry is causing ... efficiency , Deloitte offers a suite of solutions ... issues impacting efficient cost optimization: labor resource analysis, revenue ... services facilitate better outcomes and better economics ...
(Date:6/24/2016)... 2016 Dublin ... addition of the " Global Markets for Spectroscopy ... This report focuses on the ... review, including its applications in various applications. The report ... includes three main industries: pharmaceutical and biotechnology, food and ...
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are ... for this recognition are considered among the top 2 percent of lawyers practicing within ... of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening ... Talker Award, an essay contest in which patients and their families pay tribute to ... at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s ... the world, and the most handsome men, look naturally attractive. Plastic surgery should ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, ... economy by obtaining investment capital for emerging technology companies. SCP has delivered ... already resulted in more than a million dollars of capital investment for five ...
Breaking Medicine News(10 mins):